<DOC>
	<DOCNO>NCT01155193</DOCNO>
	<brief_summary>Evaluation Respiratory Syncytial Virus ( RSV ) Hospitalization impact risk factor preterm infant , infant congenital heart disease infant bronchopulmonary abnormality development immunize Synagis .</brief_summary>
	<brief_title>Prospective , Study Use Palivizumab ( Synagis ) High Risk Children Germany</brief_title>
	<detailed_description>The Synagis Post-Marketing Observational Study ( PMOS ) provide information : - drug administer - risk factor distribute investigated population - often RSV-related hospitalization ICU admission occur - compliance rate among parent SynagisÂ® infant</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Children bear 35 week gestation less less 6 month age onset Respiratory syncytial virus season Children le 2 year age require treatment bronchopulmonary dysplasia within last 6 month . Children le 2 year age hemodynamically significant congenital heart disease . Children known hypersensitivity Palivizumab component formulation , humanize monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Children</keyword>
	<keyword>Pre-term infant</keyword>
	<keyword>Congenital heart disease</keyword>
	<keyword>Infection</keyword>
	<keyword>Respiratory syncytial virus</keyword>
</DOC>